| (Astex) SGI-110-07 / ASTRAL 3 | A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents | Leber, Dr Brian | Open | NCT02907359 |
| MCRN 004 | A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma. | Kouroukis, Dr Tom | Open | NCT03215524 |
| (CCTG) LY.17 | A MULTI-STAGE RANDOMIZED PHASE II STUDY OF NOVEL COMBINATION THERAPY IN THE TREATMENT OF RELAPSED AND REFRACTORY AGGRESSIVE B-CELL LYMPHOMA | Fraser, Dr Graeme | On hold | NCT02436707 |
| (Celgene) AZA-MDS-003 | A phase 3, multicentre, randomized, double-blind study to compare with efficacy and safety of oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with red blood cell transfusion-dependent anemia and thrombocytopenia due to IPSS lower-risk myelodysplatic syndromes | Leber, Dr Brian | On hold | NCT01566695 |
| (Novartis) CINC424C2301 / REACH 2 | A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation | Leber, Dr Brian | On hold | NCT02953678 |
| (Novartis) CINC424D2301 / REACH 3 | A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH 3) | Foley, Dr Ronan | On hold | NCT03112603 |
Find a Trial
Contact Us